FMS vs NKTR

For growth investors, Fresenius Medical Care AG & Co.

KGaA (FMS) is the stronger pick with 1. 5% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11. 0x trailing P/E (10. 5x forward), making it the more compelling value choice. Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Fresenius Medical Care AG & Co.

KGaA (FMS) delivered a total return of -35. 9%, compared to -72. 3% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: FMS returned -35. 1% versus NKTR's -59. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Fresenius Medical Care AG & Co.

KGaA (FMS) is the lower-risk stock at 0. 49β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 276% more volatile than FMS relative to the S&P 500. On balance sheet safety, Fresenius Medical Care AG & Co. KGaA (FMS) carries a lower debt/equity ratio of 76% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Fresenius Medical Care AG & Co.

KGaA (FMS) is pulling ahead at 1. 5% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Fresenius Medical Care AG & Co. KGaA grew EPS 82. 6% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, FMS leads at 0. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Fresenius Medical Care AG & Co.

KGaA (FMS) is the more profitable company, earning 5. 0% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 5. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FMS leads at 9. 3% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NKTR: 59.

3% to $132. 83.

In this comparison, FMS (3.

8% yield) pays a dividend. NKTR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Fresenius Medical Care AG & Co.

KGaA (FMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 49), 3. 8% yield). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FMS: -35. 1%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FMS is a mid-cap deep-value stock; NKTR is a small-cap quality compounder stock. FMS pays a dividend while NKTR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.